Posted by Michael Wonder on 03 Mar 2026
ICER publishes special report on treatment for ulcerative colitis and Crohn’s disease as part of CMS public comment process on Medicare drug price negotiations
3 March 2026 - The ICER today posted a special report on Entyvio (vedolizumab, Takeda) for the treatment of ulcerative colitis and Crohn’s disease.
This report will be submitted to the CMS as part of the 2026 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2028.
